Neurocrine Biosciences Inc vs Rio Tinto (ADR) — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Rio Tinto (ADR) trades at $94.51 (market cap $150.89B). The key difference: Rio Tinto (ADR) is far larger — about 10.5× Neurocrine Biosciences Inc's market cap, and Rio Tinto (ADR) pays a 4.98% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Rio Tinto (ADR) for 10 Days on average.
| NBIX | RIO | |
|---|---|---|
Market Cap | $14.36B | $150.89B |
Volume | 1,237,180 | 1,492,444 |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $112.04 |
52-Week Low | $123.10 | $65.44 |
Typical Hold Time | 23 Days | 10 Days |
Enterprise Value | $14.37B | $164.24B |
Dividend Yield | — | 4.98% |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Rio Tinto is a global mining company that produces metals and minerals including iron ore, aluminium, copper, and lithium. Its operations supply materials used in construction, manufacturing, transportation, and energy systems.
Read more on RIO →